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Abstract
Background: In tuberculosis (TB) endemic areas, Mycobacterium tuberculosis is an important but easily misdiagnosed
pathogen in community-acquired pneumonia (CAP). However, the occurrence of concomitant pulmonary tuberculosis (PTB)
in hospitalized healthcare-associated pneumonia (HCAP) has never been investigated.
Methods and Findings: Seven hundred and one hospitalized HCAP and 934 hospitalized CAP patients from six medical
centers in Taiwan were included in this nationwide retrospective study. Concomitant PTB was defined as active PTB
diagnosed within 60 days of admission due to HCAP or CAP. The predictors for concomitant PTB and the impact of PTB on
the outcomes of pneumonia were investigated. Among the enrolled subjects, 21/701 (3%) of the HCAP patients and 25/934
(2.7%) of the CAP patients were documented to have concomitant PTB. In multivariate analysis, a history of previous anti-TB
treatment (OR=5.84, 95% CI: 2.29–20.37 in HCAP; OR=3.33, 95% CI: 1.09–10.22 in CAP) and escalated pneumonia severity
index (PSI) scores (OR=1.014, 95% CI: 1.002–1.026, in HCAP; OR=1.013, 95% CI: 1.001–1.026, in CAP) were independent
predictors for concomitant PTB in both CAP and HCAP patients. Regarding treatment outcomes, HCAP patients with
concomitant PTB were associated with more acute respiratory failure within 48 hours of admission (47.6% vs. 22.6%,
p=0.008), higher intensive care unit admission rate (61.9% vs. 35.7%, p=0.014), longer hospitalization (39.6634.1 vs.
23.7627 days, p=0.009), and higher in-hospital mortality (47.6% vs. 26.3%, p=0.03) than those without concomitant PTB.
Exposure to certain groups of antibiotics for the treatment of pneumonia was not associated with the occurrence of
concomitant PTB.
Conclusions: In HCAP patients, the occurrence of concomitant PTB is comparable with that in CAP patients and associated
with higher PSI scores, more acute respiratory failure, and higher in-hospital mortality.
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Introduction
Tuberculosis (TB) is an important infectious disease associated
with high mortality and morbidity. According to estimates of the
World Health Organization (WHO), there were 9.4 million
incident cases of TB, and 1.7 million people who died from TB
worldwide in 2009 [1]. In Taiwan, the incidence and mortality of
TB were 62 and 3.3 cases per 100,000 population, respectively, in
2008 [2]. Due to the non-specific symptoms and diverse
radiographic presentations, it is not always easy to differentiate
pulmonary tuberculosis (PTB) from bacterial pneumonia in a
clinical setting [3]. In TB endemic areas, TB studies are frequently
ordered in patients treated for community-acquired pneumonia
(CAP). Empirical antibiotics, especially newer fluoroquinolones
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36832(FQNs), are used with caution as they may delay the diagnosis of
PTB and are associated with worse outcomes [4,5].
Healthcare-associated pneumonia (HCAP) is a relatively new
category of pneumonia that was first defined in 2005 with unique
microbiological characteristics and treatment outcomes [6,7]. It
represents a pulmonary infection that occurs before hospitalization
in patients who had contact with or an exposure history to a
healthcare environment [8]. HCAP patients are generally older
with multiple comorbidities, which are also risk factors for the
development of PTB. However, the occurrence of concomitant
PTB in HCAP patients has never been evaluated. Unawareness of
concomitant PTB in hospitalized HCAP patients may lead to a
delayed diagnosis and transmission of Mycobacterium tuberculosis
(MTB) in healthcare facilities. The main purpose of the present
study was to investigate the occurrence and clinical predictors of
concomitant PTB in hospitalized HCAP patients, and compare
them to those of CAP patients. The relationship of exposure to
antibiotics for the treatment of pneumonia to PTB occurrence,
and the impact of concomitant PTB in the outcomes of
pneumonia in these patients were also evaluated.
Materials and Methods
Ethics
This study was approved by the Institutional Review Boards of
Taipei Veterans General Hospital; Kaohsiung Chang Gung
Memorial Hospital; Taichung Veterans General Hospital; Na-
tional Taiwan University Hospital; National Cheng-Kung Uni-
versity Hospital; and China Medical University Hospital. Being a
retrospective study, informed consent was waived according to the
regulations of the Department of Health, Taiwan.
Patients
This was a nationwide retrospective cohort study conducted at
six tertiary medical centers in Taiwan. Patients admitted to these
hospitals with a final diagnosis of HCAP from 1 January 2007 to
31 December 2007 were eligible for inclusion. We also included
hospitalized CAP patients from these hospitals during the same
study period for comparison. HCAP and CAP were defined as in
previous reports [9,10]. Patients presenting with pneumonia
diagnosed within 48 hours after hospitalization were included as
HCAP if at least one of the following criteria was satisfied: (1)
receiving regular dialysis at an outpatient clinic; (2) receiving
radiation therapy or chemotherapy at an outpatient clinic; (3)
undergoing repeated hospitalization within 90 days prior to the
episode of current pneumonia; or (4) residing in a nursing home.
Pneumonia patients diagnosed within 48 hours after hospitaliza-
tion were included as CAP if none of the HCAP criteria were met.
The diagnosis of pneumonia was confirmed by chest radiographic
manifestations with the growth of microorganisms from cultures of
respiratory specimens or clinical improvement after antibiotic
therapy. Patients who had lung cancer with obstructive pneumo-
nitis, inadequate data for review, or were younger than 18 years
old were excluded from analysis.
Clinical evaluation
Demographic profiles (age, sex), clinical characteristics (smoking
habits and comorbidities), and usage of antibiotics were obtained
Table 1. Demographic profiles between hospitalized HCAP and CAP patients
a.
Overall, =1635 Type of pneumonia P value
CAP, n=934 HCAP, n=701
Mean age (SD) 72.8 (15.7) 72.5(16.6) 73.1 (14.5) 0.47
Male gender 1172 (71.7%) 674 (72.2%) 498 (71%) 0.62
Smoking habit 603 (36.9%) 329 (35.2%) 274 (39.1%) 0.11
Previous anti-TB treatment 82 (5%) 49 (5.2%) 33 (4.7%) 0.62
Comorbidities
Malignancy 322 (19.7%) 79 (8.5%) 243 (34.7%) ,0.001
Renal insufficiency 199 (12.2%) 69 (7.4%) 130 (18.5%) ,0.001
Chronic liver disease 86 (5.3%) 41 (4.4%) 45 (6.4%) 0.07
Diabetes 443 (27.1%) 235 (25.2%) 208 (29.7%) 0.042
COPD 250 (15.3%) 154 (16.5%) 96 (13.7%) 0.12
Pneumonia severity
PSI score 133.3 (34.5) 126.5 (31.7) 142.3 (36.0) ,0.001
CURB65 score 1.81 (1.07) 1.77 (1.05) 1.87 (1.10) 0.08
Chest film presentation
Upper lung involvement 661 (40.4%) 339 (36.3%) 322 (45.9%) ,0.001
Bilateral lung involvement 703 (43%) 378 (40.5%) 325 (46.4%) 0.017
TB testing when admission 562 (34.4%) 375 (40.1%) 187 (26.7%) ,0.001
Pathogen in sputum culture (n=744)
Gram-positive bacteria 209 (28.1%) 131 (31.3%) 78 (24%) 0.08
Gram-negative bacteria 535 (71.9%) 288 (68.7%) 247 (76%) 0.06
aThe data are presented as n (%) unless otherwise stated.
HCAP, healthcare-associated pneumonia; CAP, community acquired pneumonia; TB, tuberculosis; SD, standard deviation; COPD, chronic obstructive pulmonary disease;
PSI, pneumonia severity index; CURB65, confusion, urea, respiratory rate, blood pressure, age 65.
doi:10.1371/journal.pone.0036832.t001
Concomitant PTB in Hospitalized HCAP Patients
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36832from medical records. A history of previous anti-TB treatment was
determined according to the registration database of the Centers
for Disease Control (CDC), Taiwan, and the medical records in
each study hospital. The chest radiographs on the day of
admission were reviewed by the responsible pulmonologist at
each hospital. The pneumonia scoring indices, including CURB65
(confusion, urea, respiratory rate, blood pressure, age 65) score
and pneumonia severity index (PSI) were calculated as described
in previous studies [11,12]. The antibiotics used during hospital-
ization were classified as cephalosporin, penicillin, macrolide, and
newer quinolone (including moxifloxacin and levofloxacin) groups.
Exposure to these groups of antibiotics was defined if the
antibiotics had been used within the last 7 days. The outcomes
of pneumonia were evaluated by organ dysfunction within
48 hours, intensive care unit (ICU) admission rate, length of
hospital stay, number of antibiotics used, long-term ventilator
dependence rate, and mortality rate. Organ dysfunction was
defined as per a previous study [13]. The severity of pneumonia
was stratified according to the PSI scores (#130, 131,149, and
$150) and the number of organ dysfunctions to compare with the
occurrence of concomitant PTB. All the patients were followed
until mortality or discharge after an improvement in pneumonia.
Identification of concomitant PTB
Asconventional TBculture methodsgenerallyrequire sixtoeight
weeks to obtain the final results, pneumonia patients with active
PTB diagnosed within 60 days of admission were defined as cases
with concomitant PTB. The occurrence of PTB was determined
according to the records in the CDC registration database, Taiwan.
Only PTB that was proven by TB cultures or typical pathological
findings from respiratory specimens were included for analysis.
Statistical analysis
StatisticalanalysiswasperformedusingSPSSversion17.0software
(SPSS, Chicago, IL, USA). Continuous variables between subgroups
were compared with Mann-Whitney U or independent t tests, and
categorical variables were compared using Pearson’s chi-square or
Fisher’s exact tests. Binary logistic regression analysis with stepwise
selection was performed to determine the independent variables for
the occurrence of concomitant PTB, and odds ratios with their 95%
confidence intervals were presented. A p value less than 0.1 in the
univariate analysis was required for a variable to be entered into the
multivariate model. Survival time was estimated by the Kaplan-
Meier method, and the log-rank test was used to compare mortality in
HCAP and CAP patients with or without concomitant PTB.
Censored analysis was used because the observation time was limited
by discharge from the hospitals. All tests were two-tailed, and a p
value less than 0.05 was considered to be statistically significant.
Results
Patients characteristics
During the study period, a total of 718 HCAP patients were
identified from the six study hospitals. Of these patients, seven
Table 2. Demographic profiles and clinical characteristics of CAP and HCAP patients with and without concomitant pulmonary
tuberculosis
a.
Overall patient, n=1635 P value CAP patients, n=934 P value HCAP patients, n=701 P value
With TB,
n=46
Without TB,
n=1589
With TB,
n=25
Without
TB, n=909
With TB,
n=21
Without TB,
n=680
Mean age (SD) 76.2 (15.3) 72.7 (15.7) 0.14 74.1 (16.8) 72.5 (16.6) 0.65 79.6 (13.4) 72.9 (14.5) 0.034
Male gender 38 (82.6%) 1134 (71.4%) 0.10 22 (88%) 652 (71.7%) 0.07 16 (76.2%) 482 (70.9%) 0.60
Smoking habit 20 (43.5%) 583 (36.7%) 0.35 12 (48%) 317 (34.9%) 0.18 8 (38.1%) 266 (39.1%) 0.93
Previous anti-TB treatment 9 (19.6%) 73 (4.6%) ,0.001 4 (16%) 45 (5%) 0.015 5 (23.8%) 28 (4.1%) ,0.001
Comorbidities
Malignancy 14 (30.4%) 308 (19.4%) 0.06 5 (20%) 74 (8.1%) 0.036 9 (42.9%) 234 (34.4%) 0.42
Renal insufficiency 6 (13%) 193 (12.1%) 0.85 3 (12%) 66 (7.3%) 0.37 3 (14.3%) 127 (18.7%) 0.61
Chronic liver disease 1 (2.2%) 85 (5.3%) 0.34 1 (4%) 40 (4.4%) 0.92 0 45 (6.6%) 0.39
Diabetes 14 (30.4%) 429 (27%) 0.61 8 (32%) 227 (25%) 0.42 6 (28.6%) 202 (29.7%) 0.91
COPD 11 (23.9%) 239 (15%) 0.10 7 (28%) 147 (16.2%) 0.12 4 (19%) 92 (13.5%) 0.47
Pneumonia severity
PSI score (SD) 149.9 (35.7) 132.8 (34.4) 0.001 140.3 (36.1) 126.1 (31.5) 0.033 161.3 (32.5) 141.7 (36.0) 0.017
CURB65 score (SD) 1.91 (1.05) 1.81 (1.08) 0.60 1.80 (1.00) 1.77 (1.05) 1.00 2.05 (1.12) 1.87 (1.10) 0.46
Chest film presentation
Upper lung involvement 19 (41.3%) 642 (40.4%) 0.90 8 (32%) 331 (36.4%) 0.65 11 (52.4%) 311 (45.7%) 0.55
Bilateral lung involvement 24 (52.2%) 679 (42.7%) 0.20 12 (48%) 366 (40.3%) 0.44 12 (57.1%) 313 (46%) 0.31
Type of pneumonia 0.73 - -
CAP 25 (54.3%) 905 (57%) - - - -
HCAP 21 (45.7%) 684 (43%) - - - -
TB testing on admission 25 (54.3%) 537 (33.8%) 0.004 16 (64%) 359 (39.5%) 0.014 9 (42.9%) 178 (26.2%) 0.089
aThe data are presented as n (%) unless otherwise stated.
HCAP, healthcare-associated pneumonia; CAP, community acquired pneumonia; TB, tuberculosis; SD, standard deviation; COPD, chronic obstructive pulmonary disease;
PSI, pneumonia severity index; CURB65, confusion, urea, respiratory rate, blood pressure, age 65.
doi:10.1371/journal.pone.0036832.t002
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and 10 were excluded due to incomplete data for review. In total,
701 hospitalized HCAP patients were included for analysis.
Among these patients, 323 (46.1%) were hospitalized in an acute
care hospital for two or more days within 90 days before the
current admission; 164 (23.4%) resided in a nursing home or long-
term care facility; 136 (19.4%) had received intravenous antibiotic
therapy, chemotherapy, or wound care within the past 30 days of
the current infection; and 77 (11%) attended a hospital or
hemodialysis clinic. We also included 934 CAP patients from the
study hospitals for comparison. The flow diagram showing the
number of cases and reasons for exclusion is shown in Figure S1.
The demographic characteristics of the HCAP and CAP patients
are shown in Table 1. Compared with the CAP patients, the
HCAP patients were more likely to have a malignancy, renal
insufficiency, diabetes, higher PSI score, and present with upper
lung and/or bilateral lung involvement.
The pathogens isolated from respiratory specimens of the
included patients are shown in Table S1.
Occurrence of concomitant PTB and clinical predictors
Seven HCAP patients had active PTB on admission, and a
further 14 were diagnosed with PTB within 60 days after
admission. Six CAP patients had active PTB on admission, and
a further 19 were diagnosed with PTB within 60 days. The
occurrence of concomitant PTB was comparable between the
HCAP and CAP patients (3% vs. 2.7%, p=0.73).
Table 3. Relationships between antibiotics exposure and the occurrence of concomitant pulmonary tuberculosis in HCAP and CAP
patients
a.
Antibiotics exposure CAP patients, n=934 P value HCAP patients, n=701 P value
With TB, n=25 Without TB, n=909 With TB, n=21 Without TB, n=680
Penicillin
Yes 15 (2.4%) 602 (97.6%) 0.52 16 (3.9%) 395 (96.1%) 0.10
No 10 (3.2%) 307 (96.8%) 5 (1.7%) 285 (98.3%)
Cephalosporin
Yes 6 (3.4%) 171 (96.6%) 0.51 3 (1.7%) 169 (98.3%) 0.27
No 19 (2.5%) 738 (97.5%) 18 (3.4%) 511 (96.6%)
Macrolide
Yes 5 (2.3%) 210 (97.7%) 0.72 1 (2.6%) 38 (97.4%) 1.00
No 20 (2.8%) 699 (97.2%) 20 (3%) 642 (97%)
Carbapenem
Yes 0 17 (100%) 1.00 0 27 (100%) 1.00
No 25 (2.7%) 892 (97.3%) 21 (3.1%) 653 (96.9%)
Newer fluoroquinolones
b
Yes 4 (2%) 192 (98%) 0.47 4 (2.5%) 155 (97.5%) 0.69
No 21 (2.9%) 717 (97.1%) 17 (3.1%) 525 (96.1%)
aThe data are presented as n (%) unless otherwise stated.
bIncluded levofloxacin and moxifloxacin.
HCAP, healthcare-associated pneumonia; CAP, community acquired pneumonia; TB, tuberculosis.
doi:10.1371/journal.pone.0036832.t003
Table 4. Univariate and multivariate logistic regression analysis of predictors associated with concomitant pulmonary tuberculosis
in hospitalized HCAP and CAP patients
a.
CAP patients HCAP patients
Univariate Multivariate Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age 1.01 (0.98–1.03) 0.65 1.04 (1.003–1.086) 0.034
Male gender 2.89 (0.86–9.74) 0.07 1.32 (0.48–3.64) 0.60
Previous anti-TB treatment 3.66 (1.21–11.1) 0.015 3.33 (1.09–10.22) 0.035 7.28 (2.49–21.3) ,0.001 5.84 (2.29–20.37) 0.001
Malignancy 2.82 (1.03–7.72) 0.036 1.43 (0.59–3.44) 0.42
Upper lobe involvement 0.82 (0.35–1.93) 0.65 1.31 (0.55–3.11) 0.55
PSI score 1.01 (1.002–1.027) 0.033 1.013 (1.001–1.026) 0.038 1.015 (1.003–1.026) 0.015 1.014 (1.002–1.026) 0.023
aUnivariate and multivariate OR are derived from logistic regression analysis with stepwise selection procedure.
HCAP, healthcare-associated pneumonia; CAP, community acquired pneumonia; TB, tuberculosis; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0036832.t004
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CAP patients with or without concomitant PTB are shown in
Table 2. In the HCAP group, patients with concomitant PTB were
more likely to be older in age (79.6613.4 vs. 72.9614.5 years,
p=0.034), have a history of previous anti-TB treatment (23.8% vs.
4.1%, p,0.001), and have higher PSI scores (161.3632.5 vs.
141.7636, p=0.017), as compared with those without concom-
itant PTB. In the CAP group, patients with concomitant PTB
were more likely to have a previous history of anti-TB treatment
(16% vs. 5%, p=0.015), malignancy (20% vs. 8.1%, p=0.036),
and higher PSI scores (140.3636.1 vs. 126.1631.5, p=0.033).
Figure 1. Occurrence of concomitant PTB among hospitalized HCAP and CAP patients with various severity. Patients are divided
according to (A) PSI scores and (B) number of organ dysfunctions. HCAP, healthcare-associated pneumonia; CAP, community acquired pneumonia;
PSI, pneumonia severity index; PTB, pulmonary tuberculosis.
doi:10.1371/journal.pone.0036832.g001
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occurrence of concomitant PTB is shown in Table 3. In both
HCAP and CAP patients, the exposure to certain groups of
antibiotics were comparable between patients with or without
concomitant PTB.
In multivariate analysis, higher PSI scores (OR=1.014, 95%
CI: 1.002–1.026 in HCAP; OR: 1.013, 95% CI: 1.001–1.026 in
CAP) and a previous history of anti-TB treatment (OR=5.84,
95% CI: 2.29–20.37 in HCAP; OR: 3.33, 95% CI: 1.09–10.22 in
CAP) were independent predictors of concomitant PTB in both
HCAP and CAP patients (Table 4).
The occurrence of concomitant PTB in HCAP and CAP
patients stratified by the severity of PSI scores and the number of
organ dysfunctions is shown in Figure 1. The occurrence of
concomitant PTB increased as the PSI scores increased. Patients
with PSI scores $150 had significantly more concomitant PTB
than those with PSI scores #130, in both the HCAP (p=0.016)
and CAP (p=0.034) groups. The occurrence of concomitant PTB
also increased as the number of organ dysfunctions increased,
although without statistical significance.
The demographic characteristics of the HCAP and CAP
patients with or without concomitant PTB within 90 days and
their clinical predictors are shown in Table S2 and Table S3.
Impact of concomitant PTB in outcomes of the
pneumonia patients
The treatment outcomes of the HCAP and CAP patients with
or without concomitant PTB are shown in Table 5. In the HCAP
group, patients with concomitant PTB had more acute respiratory
failure within 48 hours of admission (47.6% vs. 22.6%, p=0.008),
higher ICU admission rate (61.9% vs. 35.7%, p=0.014), and
longer hospital stay (39.6634.1 days vs. 23.7627 days, p=0.009)
compared to those without concomitant PTB. In the CAP group,
patients with concomitant PTB had a higher probability of ICU
admission (44% vs. 19.7%, p=0.003) and longer hospital stay
(32627.4 days vs. 19620.3 days, p=0.002).
Regarding mortality, the in-hospital mortality rate was higher in
the HCAP patients with concomitant PTB (47.6% vs. 26.3%,
p=0.03) compared to those without PTB, although the 30-day
and 60-day mortality rates were similar. The mortality rates were
comparable in the CAP patients with or without concomitant
PTB. Kaplan-Meier analysis of survival according to the presence
or absence of concomitant PTB in the HCAP and CAP patients is
shown in Figure 2. HCAP patients with concomitant PTB had
significantly higher mortality (p=0.041) compared to those
without PTB. The survival curves overlapped between CAP
patients with or without concomitant PTB.
Univariate and multivariate analysis of clinical predictors for in-
hospital mortality in CAP and HCAP patients are shown in Table
S4.
Discussion
To the best of our knowledge, this is the first study to evaluate
the predictors and outcomes of concomitant PTB in HCAP
patients in a TB endemic area. We found that the occurrence of
concomitant PTB in hospitalized HCAP patients was not rare and
was comparable to those with CAP. A history of previous anti-TB
Table 5. Impact of concomitant tuberculosis in treatment outcome of HCAP and CAP patients
a.
CAP patients, n=934 P value HCAP patients, n=701 P value
With TB, n=25
Without TB,
n=909 With TB, n=21
Without TB,
n=680
Organs dysfunction within 48 hours
Respiratory failure 3 (12%) 115 (12.7%) 0.92 10 (47.6%) 154 (22.6%) 0.008
Septic shock 4 (16%) 91 (10%) 0.33 5 (23.8%) 135 (19.9%) 0.66
Altered mental status 4 (16%) 66 (7.3%) 0.10 6 (28.6%) 145 (21.3%) 0.43
Renal dysfunction 2 (8%) 67 (7.4%) 0.91 1 (4.8%) 104 (15.3%) 0.18
Liver dysfunction 0 1 (0.1%) 1.00 0 3 (0.4%) 0.76
Coagulopathy 0 6 (0.7%) 1.00 1 (4.8%) 13 (1.9%) 0.36
Thrombocytopenia 2 (8%) 26 (2.9%) 0.14 1 (4.8%) 50 (7.4%) 0.65
ICU admission 11 (44%) 179 (19.7%) 0.003 13 (61.9%) 243 (35.7%) 0.014
Length of hospital stay (SD)
All patients 32.0 (27.4) 19.0 (20.3) 0.002 39.6 (34.1) 23.7 (27.0) 0.009
Survivors 24.5 (17.9) 18.4 (19.7) 0.19 46.2 (42.6) 23.1 (23.9) 0.002
Non-survivors 56.1 (39.3) 23.4 (24.4) 0.003 32.4 (21.4) 25.7 (34.6) 0.54
28 days hospital free day (SD) 7.2 (8.9) 11.9 (8.8) 0.008 4.2 (7.5) 7.8 (8.5) 0.039
Mean Numbers of antibiotics used (SD) 1.74 (0.69) 1.61 (0.75) 0.41 1.29 (0.46) 1.37 (0.62) 0.52
Long-term ventilator dependent 1 (4%) 18 (2%) 0.48 1 (4.8%) 32 (4.7%) 0.99
Mortality
30-day mortality 2 (8%) 73 (8%) 1.00 4 (19%) 133 (19.6%) 0.95
60-day mortality 3 (12%) 99 (10.9%) 0.86 7 (33.3%) 166 (24.4%) 0.35
In-hospital mortality 6 (24%) 106 (11.7%) 0.06 10 (47.6%) 179 (26.3%) 0.030
aThe data are presented as n (%)unless otherwise stated.
HCAP, healthcare-associated pneumonia; CAP, community acquired pneumonia; TB, tuberculosis; SD, standard deviation; ICU, intensive care unit.
doi:10.1371/journal.pone.0036832.t005
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the occurrence of PTB in both HCAP and CAP patients. We also
found that HCAP patients with concomitant PTB were associated
with worse outcomes of pneumonia, including more acute
respiratory failure, higher ICU admission rate, longer hospital
stay, and higher in-hospital mortality.
HCAP is a relatively new category of pneumonia that refers to
pneumonias that occur prior to hospital admission in patients with
specific risk factors [9]. In contrast to CAP, which is typically
attributable to antibiotic-susceptible bacteria [14], patients with
HCAP have a higher probability of being infected with antibiotic-
resistant bacteria, and HCAP is usually associated with multiple
comorbidities, higher disease severity and higher mortality [15–
17]. There is a lack of an ideal scoring index for HCAP, however
the applicability of PSI scores and CURB65 was reported in one
recent study [18]. Compared with the CAP patients, the HCAP
patients in our study had higher PSI scores and more advanced
pulmonary involvement on chest radiographs. These patients also
had a higher proportion of malignancies, renal insufficiency, and
diabetes, which are well documented risk factors for PTB [19,20].
Considering the multiple comorbidities and higher severity in
HCAP patients, identifying the occurrence of concomitant PTB is
an important issue, especially in TB endemic areas.
The association between CAP and PTB in TB endemic areas
has been reported in previous studies [21,22]. The latest guidelines
for CAP also recommend TB studies as initial survey in TB
endemic areas [10]. However, studies evaluating the association
between HCAP and PTB are surprisingly rare. According to the
latest HCAP guidelines, PTB should be considered only in non-
responders to antibiotics treatment [9]. In our study, 3% of the
hospitalized HCAP patients were documented to have concom-
itant PTB, which is comparable to the CAP patients. This
indicates that PTB is not rare in HCAP patients in TB endemic
areas, and that clinicians should keep PTB in mind when
evaluating HCAP patients. Early diagnosis of concomitant PTB
in HCAP is also important to prevent TB transmission in medical
facilities.
The identification of clinical predictors associated with PTB in
pneumonia patients helps in the early recognition of PTB. A
prospective study performed in the Unites States indicated that
typical CXR presentations, a history of previous TB, immigration
status, weight loss and homelessness are independent predictors for
PTB in patients presenting to the emergency department with a
diagnosis of pneumonia [23]. In line with that report, a history of
previous anti-TB treatment was an independent clinical predictor
of PTB in the present study. We also found that higher PSI scores
were independently associated with the presence of concomitant
PTB in both HCAP and CAP patients. By comparison, age was
not an independent predictor for concomitant PTB in multivariate
analysis. One possible explanation is that the calculation of PSI
scores already takes the factor of age into consideration. Another
possible reason is that the correlation between age and higher
disease severity may lessen the statistical significance of age in
multivariate analysis. Furthermore, we clearly demonstrated that
patients with PSI scores .130, which have been reported to have
the highest risk of mortality [12], had a higher occurrence of PTB
compared to those with PSI scores #130. Patients with higher
disease severity may be associated with more comorbidities that
increase the risk of PTB occurrence. Meanwhile, the presence of
concomitant PTB may also complicate the disease course of
pneumonia and increase disease severity. The higher disease
severity and possible complications associated with anti-TB
treatment may further worsen the treatment outcomes of these
patients with pneumonia.
The impact of PTB on the outcomes of hospitalized pneumonia
patients has been evaluated before with controversial results.
Penner et al. reported higher mortality in patients with pneumonia
and PTB requiring mechanical ventilation compared to those
without PTB [24]. Another case control study reported compa-
rable mortality rates between ICU admitted pneumonia patients
Figure 2. Kaplan-Meier survival curves of hospitalized pneu-
monia patients with or without concomitant PTB. Patients with
(A) HCAP and (B) CAP were stratified by the presence or absence of
concomitant PTB within 60 days. HCAP, healthcare-associated pneu-
monia; CAP, community acquired pneumonia; PTB, pulmonary tuber-
culosis.
doi:10.1371/journal.pone.0036832.g002
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HCAP patients with concomitant PTB were associated with
higher in-hospital mortality. In multivariate analysis, the indepen-
dent predictors for mortality of the HCAP patients were the
presence of malignancy, higher PSI scores, higher CURB65
scores, and bilateral involvement in chest radiograms, but did not
include the occurrence of concomitant PTB (data not shown). Our
findings imply that the worse treatment outcomes of HCAP
patients with PTB are more likely to result from the underlying
comorbidities and higher disease severity, but not TB disease per
se. Nevertheless, our findings still have important clinical
implications. Given the fact that concomitant PTB is not rare in
hospitalized HCAP patients, and that the higher disease severity in
these patients lead to higher mortality, it is important that
clinicians should consider PTB in HCAP patients with more
comorbidities and higher severity. In addition, we also found that
HCAP patients with concomitant PTB had more acute respiratory
failure within 48 hours of admission, higher ICU admission rate,
and longer hospital stay. Therefore, early diagnosis and early
treatment of PTB may not only potentially reduce mortality, but
also avoid TB transmission within healthcare facilities.
Our study has several limitations. This is a retrospective study
and some clinical information may be incomplete. All of the
participating hospitals are tertiary medical centers, and the
enrolled patients were of older age with more comorbidities.
Therefore, the incidence of concomitant PTB in these patients
may be higher than that of the general population. Nevertheless,
our findings can be applied to patients with more comorbidities.
TB testing on admission was not routinely done in each patient.
The occurrences of concomitant PTB may be underdiagnosed in
HCAP group because of the lower TB testing rate on admission.
However, our findings also clearly indicate the lack of awareness of
PTB by clinicians, especially in HCAP patients. We did not stratify
deaths as being due to either TB or HCAP in the study design
because it is not always easy to clarify the causes of death in a
retrospective study. All-cause mortality is more objective and
applicable in clinical practice. Being a retrospective study, the
MTB specimens from our patients could not be completely
obtained, so drug susceptibility profiles were not demonstrated.
Finally, this study was conducted in a TB endemic area with a low
HIV prevalence rate, which may limit the application of our
findings to non-HIV endemic areas.
In conclusion, our findings suggest that the occurrence of
concomitant PTB in hospitalized HCAP patients in a TB endemic
area is not rare and frequently overlooked by clinicians. Higher
PSI scores and a history of previous anti-TB treatment were
independent predictors for concomitant PTB in both hospitalized
HCAP and CAP patients. Regarding treatment outcomes,
hospitalized HCAP patients with concomitant PTB were associ-
ated with higher in-hospital mortality and more acute respiratory
failure within 48 hours. These patients also had a higher ICU
admission rate and longer hospital stay, which may lead to TB
transmission if the diagnosis of PTB is delayed. Our results provide
important evidence to remind clinicians to keep a high suspicion of
and identify concomitant PTB early in hospitalized HCAP
patients by examining the risk factors and pneumonia severity.
Further prospective studies are warranted to elucidate this issue,
especially in TB endemic areas.
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